Mature B-Cell Non-Hodgkin Lymphoma — Trials

Mature B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 792
Recruiting: 401
Ph III recruiting: 40
Growth YoY: +8%
Industry share: 24%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (393)

clinicaltrialsPublishedShowing 501–550 of 2,506 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02029443	ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia	active not recruiting	Phase 1 / Phase 2	306	Acerta Pharma BVINDUSTRY	3	May 5, 2026	clinicaltrials
NCT03506373	Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia	terminated	Phase 2	21	Mayo ClinicOTHER	1	May 5, 2026	clinicaltrials